The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.

Sarepta Therapeutics (NASDAQ:SRPT) surges 40% post-market after strategic restructuring, workforce cuts, pipeline focus, and ...

Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at ...

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock plummet in premarket trading Friday following the disclosure of a patient ...

US rare disease meds developer Sarepta Therapeutics late yesterday announced a strategic restructuring plan designed to ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...

On June 25, HC Wainwright & Co. downgraded the stock from Neutral to Sell and cut its price target on the stock from $40 to ...

Stocks turned in a lackluster performance Friday as Wall Street took a breather at the end of the first week of ...

Review the current Sarepta Therapeutics Inc (SRPT:XMEX) dividend yield and history to decide if SRPT is the best investment for you.

On the increasingly wary side is Macro Tourist blog author and former institutional trader Kevin Muir, who in our call of the ...